Clinical Trial Update: A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 pilot study of Oncaspar (pegaspargase) plus dexamethasone in relapsed or refractory T-cell lymphoma was terminated early.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Oncaspar (pegaspargase)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: T-Cell Lymphoma, Relapsed T-Cell Lymphoma | EARLY_Phase 1 | Status: TERMINATED